My Cart (0 items) Help
Canada (change)
Home → Medicine → Cardiology
By Daniel J. Lenihan, MD, FACC and Douglas B. Sawyer, M.D., Ph.D., FACC
168 pagesCopyright 2011$128.99, Hardcover, Reference
A title in the The Clinics: Internal Medicine Series.
Availability:This title is currently out of stock. We will ship as soon as we receive our stock.
As the number of effective anti-neoplastic agents has grown, there has been a concomitant increase in side effects. Cardiotoxicity, and specifically LV dysfunction, remains the limiting factor for many such agents, and is the focus of growing research and clinical emphasis. This issue summarizes for the heart failure specialist the possible ways that chemotherapeutic agents might cause cardiotoxicity as well as the methods for detecting, treating and preventing cardiotoxicity.
By Daniel J. Lenihan, MD, FACC, Professor of Medicine, Director, Cardio-Oncology Center of Excellence, Advanced Heart Failure, Clinical Research, Cardiovascular Division, Washington University in St. Louis, St. Louis Missouri and Douglas B. Sawyer, M.D., Ph.D., FACC , Maine Medical Center Department of Cardiac Services Portland, ME, USA